Locate Therapeutics Ltd (“Locate”), the regenerative medicine development company, today announced the appointment of Dr Ian Wilding as Chairman of the Board of Directors.
Dr Wilding is an internationally respected key opinion leader in drug development and a serial entrepreneur. His background includes strong scientific, business, managerial and deal-making expertise. Dr Wilding has previously founded, managed and developed a number of successful bioscience start-up companies, including Pharmaceutical Profiles (recipient of a Frost & Sullivan Excellence in Technology Award) which, as Chief Executive, he grew to over 110 employees and a 10 Million GBP turnover. In a long career commercializing science, he was also the co-founder of R5 Pharmaceuticals, Modern Biosciences, Zysis and BioCity Nottingham. In addition to his Board roles, Dr Wilding currently consults for over 30 pharmaceutical and biotech companies on drug development and commercialization issues.
Dr Robin Quirk, Managing Director of Locate, commented: “Ian brings to Locate an extensive experience in transforming bioscience innovations into successful commercial therapeutics. He will be a valuable addition to our team and his significant insights will be invaluable to us as we continue the clinical development of products. We welcome Ian and look forward to drawing upon his proven strategic, operational and scientific judgments”.
Dr Wilding commented “I look forward to working with the team at Locate to drive the continued growth of the company. The company has great potential to deliver innovative therapies leveraged from a strong patent base and is at an exciting phase of its development”
For further information please email email@example.com or call +44 (0)115 784 0041.